Inhalation of Macrolides: A Novel Approach to Treatment of Pulmonary Infections

Advances in Experimental Medicine and Biology

Volumn 839, Issue , 2015, Pages 13-24

  Siekmeier, R ^a   Hofmann, T ^b   Scheuch, G ^b  

^a UNIVERSITY OF BONN   (Germany)

^b Activaero GmbH   (Germany)

Author keywords

Aerosol; Antibiotics; COPD; Cystic fibrosis; Inhalation; Macrolides

Indexed keywords

BACTERIA (MICROORGANISMS); RATTUS;

AEROSOL; ANTIINFECTIVE AGENT; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; KETOLIDE; MACROLIDE; TELITHROMYCIN;

AEROSOL; ANIMAL; BRONCHIECTASIS; CYSTIC FIBROSIS; DRUG EFFECTS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; MICROBIOLOGY; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RAT;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHIECTASIS; CLARITHROMYCIN; CYSTIC FIBROSIS; ERYTHROMYCIN; HUMANS; KETOLIDES; LUNG; MACROLIDES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS;

EID: 84925023856     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/5584_2014_50     Document Type: Article

References (47)

1. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR, for COPD Clinical Research Network (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365:689-698
2. Altenburg J, de Graaf CS, van der Werf TS, Boersma WG (2011a) Immunomodulatory effects of macrolide antibiotics - Part 1: Biological mechanisms. Respiration 81:67-74
3. Altenburg J, de Graaf CS, van der Werf TS, Boersma WG (2011b) Immunomodulatory effects of macrolide antibiotics - Part 2: Advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 81:75-87
4. Altenburg J, de Graaf CS, Stienstra Y, Sloos JH, van Haren EHJ, Koppers RJH, van der Werf TS, Boersma WG (2013) Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. The BAT Randomized Controlled Trial. JAMA 309:1251-1259
5. Bilton D, Jones AL (2011) Bronchiectasis: epidemiology and causes. Eur Respir Monogr 2011(52):1-10
6. Brodt HR, Smollich M, Stille W et al (2013) Antibiotika- Therapie. Klinik und Praxis der antiinfektiösen Behandlung. Schattauer GmbH, Stuttgart. ISBN-13: 9783794525744
7. Bye PT, Lau EMT, Elkins MR (2011) Pharmacological airway clearance strategies in bronchiectasis. Eur Respir Monogr 52:239-247
8. Culic O, Erakovic V, Parnham MJ (2001) Antiinflammatory effects of macrolide antibiotics. Eur J Pharmacol 429:209-229
9. Cystic Fibrosis Foundation (2012) Cystic Fibrosis Foundation patient registry annual data report 2011. Cystic Fibrosis Foundation. Bethesda, MD. http://www.cff. org/UploadedFiles/research/ClinicalResearch/2011- Patient-Registry.pdf. Accessed 6 Jan 2014
10. Drain M, Elborn JS (2011) Assessment and investigation of adults with bronchiectasis. Eur Respir Monogr 52:32-43
11. Foweraker JE, Wat D (2011) Microbiology of non-CF bronchiectasis. Eur Respir Monogr 52:68-96
12. Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168:918-951
13. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (2013) http://www.goldcopd.org/uploads/users/files/ GOLD_Report_2013_Feb20.pdf. Accessed 6 Jan 2014
14. Hagerman JK, Hancock KE, Klepser ME (2006) Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv 3:71-86
15. Haworth CS (2011) Antibiotic treatment strategies in adults with bronchiectasis. Eur Respir Monogr 52:211-222
16. Hickey AJ, Lu D, Ashley ED, Stout J (2006) Inhaled azithromycin therapy. J Aerosol Med 19:54-60
17. Hofmann T (2012) New developments in inhaled antibiotics for the treatment of Pseudomonas aeruginosa. Curr Pharm Des 18:683-695
18. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH (2013) Development and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur J Pharm Biopharm 86:23-30
19. Jones AM, Helm JM (2009) Emerging treatments in cystic fibrosis. Drugs 69:1903-1910
20. Kanoh S, Rubin BK (2010) Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 23:590-615
21. Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus LH, Kimura H, Sugiyama Y (1987) Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 25:632-642 (in Japanese)
22. Lambrecht BN, Neyt K, GeurtsvanKessel CH (2011) Pulmonary defence mechanisms and inflammatory pathways in bronchiectasis. Eur Respir Monogr 52:11-21
23. Mauchley DC, Mitchell JD (2011) Surgery for bronchiectasis. Eur Respir Monogr 52:248-257
24. McCormick J, Mehta G, Olesen HV, Viviani L, Macek M, Mehta A, on behalf of the European Registry Working Group (2010) Comparative demographics of the European cystic fibrosis population: a cross-sectional data base analysis. Lancet 375:1007-1013
25. Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR (2008) Clinical practice and genetic counseling for cystic fibrosis and CFTRrelated disorders. Genet Med 10:851-858
26. Murray CJL, Lopez AD (1997) Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349:1269-1276
27. Murray CJL, Lopez AD (2013) Measuring the global burden of disease. N Engl J Med 369:448-457
28. Muttil P, Wang C, Hickey AJ (2009) Inhaled drug delivery for tuberculosis therapy. Pharm Res 26:2401-2416
29. Nicod LP (1999) Pulmonary defense mechanisms. Respiration 66:2-11
30. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS, on behalf of the GOLD Scientific Committee (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 163:1256-1276
31. Pilcer G, Rosiere R, Traina K, Sebti T, Vanderbist F, Amighi K (2013) New co-spray-dried tobramycin nano-particles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. J Pharm Sci 102:1836-1846
32. Rademacher J, Welte T (2011) Bronchiectasis: diagnosis and treatment. Deutsches ä rzteblatt Int 108:809-815
33. Scheuch G, Siekmeier R (2007) Novel approaches to enhance pulmonary delivery of proteins and peptides. J Physiol Pharmacol 58(Suppl. 5):615-625
34. Smith DJ, Chang AB, Bell SC (2011) Anti-inflammatory therapies in bronchiectasis. Eur Respir Monogr 52:223-238
35. Sollohub K, Janczyk M, Kutyla A, Wosicka H, Ciosek P, Cal K (2011) Taste masking of roxithromycin by spray drying technique. Acta Pol Pharm 68:601-604
36. Togami K, Chono S, Seki T, Morimoto K (2010) Aerosolbased efficient delivery of telithromycin, a ketolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections. Drug Dev Ind Pharm 36:861-866
37. Togami K, Chono S, Morimoto K (2012) Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections. J Aerosol Med Pulmon Drug Deliv 25:110-115
38. Togami K, Chono S, Morimoto K (2013) Aerosol-based efficient delivery of azithromycin to alveolar macrophages for treatment of respiratory infections. Pharm Dev Technol 18:1361-1365
39. Traini D, Young PM (2009) Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv 6:897-905
40. Tre-Hardy M, Nagant C, El Manssouri N, Vanderbist F, Traore H, Vaneechoutte M, Dehaye JP (2010) Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob Agents Chemother 54:4409-4415
41. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia- Aymerich J, Puhan MA (2012) Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 12:CD010257
42. Wenzel RP, Fowler AA, Edmond MB (2012) Antibiotic prevention of acute exacerbations of COPD. N Engl J Med 367:340-347
43. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hochey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T (2012) Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 380:660-667
44. Yao G-Y, Ma Y-L, Zhang M-Q, Gao Z-C (2013) Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis. Respiration 86:254-260
45. YawnBP (2012) Is 'GOLD' standard for themanagement of COPD in clinical practice? Drugs Context 2012:212243. doi: 10.7573/dic.212243. eCollection 2012
46. Zarogoulidis P, Kioumis I, Porpodis K, Spyratos D, Tsakiridis K, Huang H, Li Q, Turner JF, Browning R, Hohenforst-Schmidt W, Zarogoulidis K (2013) Clinical experimentation with aerosol antibiotics: current and future methods for administration. Drug Des Dev Ther 7:1115-1134
47. Zhang Y, Wang X, Lin X, Liu X, Tian B, Tang X (2010) High azithromycin loading powders for inhalation and their in vivo evaluation in rats. Int J Pharm 395:205-214